1. Indications and Usage
\nAcute Supraventricular Tachycardia:
\nEmergency treatment of tachyarrhythmias (specifically Atrial Fibrillation, Atrial Flutter, and Sinus Tachycardia) occurring during surgery or in the perioperative period .
\nSepsis-Associated Tachycardia:
\nManagement of tachycardia associated with sepsis (depending on regional labeling).
\n2. Dosage and Administration
\nRoute of Administration:
\nFor Intravenous (IV) Infusion ONLY.
\nRecommended Dosage:
\nInitial Titration: Administer by continuous infusion (typically with a syringe pump).
\nStandard Rate: Start at 0.01 to 0.04 mg\/kg\/min.
\nTitration: Adjust the rate based on heart rate (HR) and blood pressure (BP) response.
\nMaximum Dose: Generally should not exceed 20 to 40 \u00b5g\/kg\/min (depending on clinical indication) .
\nCritical Administration Instructions:
\nReconstitution: Dissolve the vial content with 5 mL or more of 0.9% Sodium Chloride Injection(Normal Saline) or 5% Dextrose Injection .
\nConcentration Limit: Do not exceed a concentration of 10 mg\/mL to avoid local irritation or skin necrosis .
\nEquipment: Use a precision infusion pump (syringe pump) for accurate control .
\n3. Mechanism of Action
\nSelective Beta-Blockade:
\nLandiolol is a \u03b21-selective adrenergic receptor antagonist. It has a high affinity for cardiac \u03b21 receptors (approx. 251 times higher than \u03b22 receptors) .
\nRapid Onset and Offset:
\nIt blocks the effects of catecholamines (epinephrine\/norepinephrine) on the heart, reducing heart rate and myocardial contractility.
\nUnique Feature: It has an extremely short half-life (approx. 4 minutes) due to rapid hydrolysis by esterases in the blood and liver, allowing for rapid titration and quick offset of effects upon discontinuation .
\n4. Safety and Warnings
\nHypotension and Bradycardia:
\nThe most common adverse reactions are a drop in blood pressure and excessive slowing of heart rate.
\nAction: Continuous monitoring of ECG and BP is mandatory. Discontinue if severe hypotension or bradycardia occurs .
\nContraindications:
\nCardiogenic shock.
\nSecond or third-degree AV block and Sick Sinus Syndrome.
\nDecompensated heart failure.
\nUntreated pheochromocytoma.
\nMetabolic acidosis (e.g., diabetic ketoacidosis) .
\n5.Adverse Reactions and Clinical Research
\nMost Common Adverse Reactions:
\nHypotension, bradycardia, nausea, headache, and injection site reactions.
\nSerious Adverse Events:
\nShock, cardiac arrest, and complete AV block (rare) .
\nClinical Research Highlights:
\nStudies confirm its efficacy in rapidly controlling heart rate in atrial fibrillation\/flutter with a safety profile that allows for immediate cessation of effects if hemodynamic instability occurs .
\n6.Drug Interactions
\nCalcium Channel Blockers:
\nConcomitant use with verapamil or diltiazem may have additive effects, increasing the risk of severe hypotension or bradycardia .
\nGeneral Anesthetics:
\nMay enhance the myocardial depressant effects of anesthetics (e.g., propofol, fentanyl) .
\nInsulin\/Antidiabetics:
\nMay mask signs of hypoglycemia (tachycardia) .
\n7.Pharmaceutical Information
\nChemical Composition:
\nActive Ingredient: Landiolol Hydrochloride.
\nAppearance: White to off-white lyophilized powder.
\nPackaging: Single-use vial (e.g., 20 mg or 100 mg).
\nStorage: Store at 2\u00b0C to 8\u00b0C (Refrigerate), protected from light .<\/p>\n","protected":false},"excerpt":{"rendered":"
Brand Name:\u6cfd\u9192 \u00ae\uff08Zexing\u00ae\uff09
\nGeneric Name: Landiolol Hydrochloride
\nStrength: 50 mg per vial
\nManufacturer: Nanjing Hicin Pharmaceutical Co., Ltd.
\nMarketing Authorization Holder: Nanjing Hicin Pharmaceutical Co., Ltd.
\nApproval Date in China: 2020
\nRegistration Number:\u56fd\u836f\u51c6\u5b57 H20203669
\nStorage: Sealed storage, protected from light and moisture at room temperature. Refer to the full package insert for detailed storage requirements.<\/p>\n
Price&Cost:Contact Us now for the best price of Landiolol Hydrochloride\uff08Zexing\uff09<\/p>\n","protected":false},"featured_media":4382,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[25,73],"product_tag":[],"class_list":["post-4381","product","type-product","status-publish","has-post-thumbnail","product_cat-injection","product_cat-chinese-innovative-drug","first","instock","shipping-taxable","product-type-simple"],"yoast_head":"\n